Yes but, what I was really pondering without understanding the numbers well ...

There are a couple things happening. Firstly revenue should be good for 2Q, though we don't know how good. Secondly though cash is going out for Algar, it may be going out slower than expected, can't really say what's going to happen on scheduling. Then there are loans and available financing that may be better used to pick up something like AOS at what seems like bargain prices. Doesn't that line up somewhat with your concerns that CLL is paying a lot of interest on idle money? And finally an acquisition might make CLL more -- or less depending on your perspective -- attractive as a takeover target?